Literature DB >> 9645609

Hsp72-mediated augmentation of MHC class I surface expression and endogenous antigen presentation.

A D Wells1, S K Rai, M S Salvato, H Band, M Malkovsky.   

Abstract

Efficient recognition of tumor cells by cytolytic T lymphocytes (CTL) is often dependent on the presentation of cytosolic peptides in the context of MHC class I molecules. This process may be influenced by various molecular chaperones. To analyze this influence, we have utilized B16 melanoma cells, which are not effectively recognized by MHC class I-restricted CTL. This resistance to CTL is apparently due to a very low level of surface MHC expression. We have found that stably transfected clones of B16 which constitutively express the human heat shock protein 72 (Hsp72) exhibit significantly increased levels of MHC class I antigens on their surface. This Hsp72-mediated up-regulation of surface MHC class I antigen represents an increase in the amount of functional MHC-peptide complexes as measured by conformation-dependent antibodies and recognition by MHC class I-restricted CTL. Expression of Hsp72 did not improve the antigen presentation defect in cells lacking the activity of the transporter associated with antigen presentation (TAP). Moreover, mice immunized with Hsp72-expressing B16 cells, but not with control-transfected B16 cells, display significantly increased resistance to a subsequent challenge with live, wild-type B16. Together, our data demonstrate that the immune recognition of tumor cells can be substantially enhanced by the suitable expression of a molecular chaperone.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9645609     DOI: 10.1093/intimm/10.5.609

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  20 in total

1.  Characterization and regulation of the major histocompatibility complex-encoded proteins Hsp70-Hom and Hsp70-1/2.

Authors:  A M Fourie; P A Peterson; Y Yang
Journal:  Cell Stress Chaperones       Date:  2001-07       Impact factor: 3.667

Review 2.  Heat shock proteins in immune reactions.

Authors:  E Weigl; P Kopecek; M Raska; S Hradilová
Journal:  Folia Microbiol (Praha)       Date:  1999       Impact factor: 2.099

3.  Hsps are up-regulated in melanoma tissue and correlate with patient clinical parameters.

Authors:  Christopher Shipp; Benjamin Weide; Evelyna Derhovanessian; Graham Pawelec
Journal:  Cell Stress Chaperones       Date:  2012-08-08       Impact factor: 3.667

4.  Green fluorescent protein as a marker for monitoring activity of stress-inducible hsp70 rat gene promoter.

Authors:  A Wysocka; Z Krawczyk
Journal:  Mol Cell Biochem       Date:  2000-12       Impact factor: 3.396

5.  The inducible Hsp70 as a marker of tumor immunogenicity.

Authors:  P R Clark; A Ménoret
Journal:  Cell Stress Chaperones       Date:  2001-04       Impact factor: 3.667

6.  DNA Vaccines for Prostate Cancer.

Authors:  Douglas G McNeel; Jordan T Becker; Laura E Johnson; Brian M Olson
Journal:  Curr Cancer Ther Rev       Date:  2012-11-01

7.  Correlation between clinicopathology and expression of heat shock protein 72 and glycoprotein 96 in human esophageal squamous cell carcinoma.

Authors:  Xiaoping Wang; Qiaoxia Wang; Huanping Lin
Journal:  Clin Dev Immunol       Date:  2010-03-10

Review 8.  Facets of heat shock protein 70 show immunotherapeutic potential.

Authors:  Stephen M Todryk; Michael J Gough; A Graham Pockley
Journal:  Immunology       Date:  2003-09       Impact factor: 7.397

9.  Heat shock protein derived from a non-autologous tumour can be used as an anti-tumour vaccine.

Authors:  David G Casey; Joanne Lysaght; Tharappel James; Andrew Bateman; Alan A Melcher; Stephen M Todryk
Journal:  Immunology       Date:  2003-09       Impact factor: 7.397

10.  Major histocompatibility complex haplotype determines hsp70-dependent protection against measles virus neurovirulence.

Authors:  Thomas Carsillo; Mary Carsillo; Zachary Traylor; Päivi Rajala-Schultz; Phillip Popovich; Stefan Niewiesk; Michael Oglesbee
Journal:  J Virol       Date:  2009-03-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.